Advances in Toxicology: Predictive Models, Biomarkers, And Safety Assessment

Jada komalisri[1], Adari Bhavyasree[1], karri Jayasrisaideepika[1], Manguluru Manojkumar[2]

[1] Student of V Pharm d, Sir C.R Reddy College of Pharmaceutical Sciences, Eluru, India

[2]Associate professor, Sir C.R Reddy College of Pharmaceutical Sciences, Eluru, India

Corresponding Author Mail – bsree105@gmail.com
DOI: 10.5281/zenodo.20699908
Received: 7 June 2026
Accepted: 17 June 2026

Abstract:

Toxicology is an essential field that focuses on understanding the harmful effects of drugs, chemicals, and environmental substances on human health. In recent years, significant advancements have improved the way toxic effects are predicted and evaluated. Modern predictive models, including computational approaches, artificial intelligence, and in vitro testing methods, are helping researchers identify potential safety concerns more efficiently and accurately while minimizing the use of animal studies. These innovations are playing an important role in improving drug development and public health protection. Biomarkers have emerged as valuable tools in toxicology for the early detection and monitoring of toxic effects. Molecular, genetic, and biochemical biomarkers are increasingly used to assess drug safety, detect organ toxicity, and support personalized treatment strategies. In addition, advanced safety assessment methods such as high-throughput screening and omics technologies have enhanced the reliability and speed of toxicity evaluation. This review highlights recent developments in predictive toxicology, the growing importance of biomarkers, and modern safety assessment approaches. It also discusses current challenges and future perspectives in creating safer therapeutic products and improving environmental safety. Overall, these advancements are transforming toxicology into a more accurate, efficient, and ethically responsible scientific discipline.

Keywords: Toxicology, Predictive models, Biomarkers, Safety assessment, Artificial intelligence, Drug safety, Omics technologies.

1.Introduction

For decades, toxicology relied heavily on observing adverse effects in laboratory animals-a pragmatic but ethically and scientifically limiting approach. The fundamental challenge has always been translating high-dose animal responses to low-dose human exposures, a gap that often introduces uncertainty into safety decisions. Today, however, the field is undergoing a quiet revolution. Driven by advances in molecular biology, computational science, and a growing societal push for humane testing methods, toxicologists are assembling a new toolkit. This article examines three interconnected pillars of that transformation: predictive models that forecast toxicity without whole-animal tests, biomarkers that signal harm before clinical symptoms appear, and modern safety assessment frameworks that integrate these tools into regulatory practice. Predictive models have moved far beyond simple structure-activity relationships. Machine learning algorithms now mine vast chemical and biological datasets to identify toxicity signals that human experts might miss. These in silico approaches do not replace experiments; rather, they prioritise which chemicals warrant further testing and suggest plausible mechanisms of toxicity. For instance, deep learning models trained on high-throughput screening data can predict hepatotoxicity or cardiotoxicity with accuracy approaching that of animal studies, but at a fraction of the time and cost [1]. Equally promising are organ-on-a-chip systems-microfluidic devices lined with human cells that recapitulate tissue-level functions. These chips can model drug-induced liver injury or lung inflammation more

faithfully than static cell cultures, offering a human-relevant window into toxic processes [2]. Parallel to these modelling advances, biomarkers have matured from vague indicators to precise molecular signatures. A biomarker today might be a specific circulating microRNA released only when kidney tubules are damaged, or a panel of proteins that appears in urine hours before creatinine rises. Such tools are transforming safety assessment because they detect injury early, often reversibly, rather than waiting for organ failure. In drug development, panels of translational biomarkers-validated in both animals and humans-allow researchers to identify safety signals in preclinical studies and then monitor the same signals in early clinical trials, reducing late-stage attrition [3]. Beyond pharmaceuticals, exposure biomarkers measured in blood or hair can reconstruct an individual's contact with environmental pollutants, enabling more accurate risk assessments for communities living near industrial sources [4]. These predictive models and biomarkers are not merely academic curiosities; they are being woven into practical safety assessment frameworks. Regulatory agencies worldwide are gradually accepting New Approach Methodologies (NAMs) for certain endpoints. The US Environmental Protection Agency, for example, has committed to reducing animal testing for pesticide safety by relying more heavily on computational models and high-throughput assays [5]. Similarly, the European Union's cosmetics ban on animal testing accelerated the validation of reconstructed human skin models for corrosion and irritation testing. These integrated approaches do not discard existing knowledge but build upon it, using weight-of-evidence reasoning that combines computational predictions, in vitro data, and limited targeted animal studies only when necessary [6].

Nevertheless, the transition is not without tension. Predictive models can be black boxes, and their predictions require careful interpretation. Biomarkers, while sensitive, may not always correlate with meaningful organ dysfunction. And regulatory safety thresholds, originally derived from animal data, need recalibration for new methods. This article will explore how researchers and regulators are addressing these challenges, aiming for a toxicology that is more human-relevant, more predictive, and less dependent on animal suffering. The advances described here do not promise a complete replacement of traditional testing-but they do offer a roadmap toward a faster, smarter, and more ethical science of safety.

Figure 1: Evolution of Modern Toxicology [39]

2.Fundamentals in Toxicology

Before examining modern predictive tools, it is essential to revisit the core principles that have guided toxicology for centuries. The discipline is built on the dose–response relationship, the concept that any substance can be harmful at a sufficient dose while being harmless at a lower one-a notion famously attributed to Paracelsus. Contemporary fundamentals, however, go further. They include the threshold of toxic concern (TTC), which establishes exposure levels below which significant risk is unlikely, and adverse outcome pathways (AOPs), which systematically link a molecular initiating event (such as receptor binding or DNA damage) through a series of key cellular events to an adverse effect at the organ or organism level. Understanding these foundational concepts ensures that novel predictive models remain grounded in biological rea lity rather than relying solely on statistical associations.[7]

3.Recent Advances in Toxicology

The last decade has witnessed a paradigm shift in toxicology from a largely descriptive science-documenting what happens after a toxic exposure-to a predictive discipline focused on anticipating harm before it occurs. Three advances exemplify this transformation. First, high-throughput transcriptomics now enables researchers to expose human cell lines to thousands of chemicals and measure genome-wide expression changes, revealing toxicity pathways without animal testing. Second, three-dimensional cell cultures such as organoids and spheroids recapitulate human tissue architecture and metabolic competence more faithfully than traditional monolayer cultures. Third, quantitative adverse outcome pathways (qAOPs) add mathematical precision to the AOP framework, allowing risk assessors to calculate the specific concentrations at which molecular perturbations translate into tissue injury. Together, these advances are forging a toxicology that is more mechanistic, more human-relevant, and more predictive.[8]

4.Predictive Models in Toxicology



Figure 2: Computational approaches for mixture toxicity prediction [40]

a) In Silico Models

In silico models use computational algorithms to forecast chemical toxicity without conducting wet-lab experiments. These serve as virtual screening tools that can evaluate thousands of compounds rapidly and inexpensively. The most traditional are quantitative structure–activity relationship (QSAR) models, which operate on the premise that structurally similar chemicals tend to exhibit similar toxic properties. More advanced approaches include read-across, where a data-poor chemical is compared to one or more structural analogues with known toxicity profiles. Public repositories such as ToxCast and ChEMBL supply the high-quality training data that underpins these models. Regulatory agencies routinely employ in silico methods for prioritisation—for example, screening environmental contaminants or cosmetic ingredients to identify that most warranting experimental confirmation. The primary limitation is reduced reliability when a chemical falls outside the model's chemical space or when the biological mechanism of toxicity is poorly understood.[9]

b) Artificial Intelligence and Machine Learning

Whereas traditional in silico models rely on predefined chemical descriptors chosen by human experts, machine learning enables algorithms to discover relevant patterns autonomously from large datasets. Deep neural networks, random forests, gradient boosting machines, and support vector machines have all been successfully applied to predict toxicological endpoints ranging from hepatotoxicity and cardiotoxicity to skin sensitisation and genotoxicity. More recently, transformer-based architectures-originally developed for natural language processing-have been adapted to read molecular structures as sequences, capturing subtle toxicophoric motifs that might escape human-designed descriptors. The principal challenge remains interpretability: an AI model may predict toxicity with high accuracy but often functions as a "black box," offering limited mechanistic insight. Ongoing research focuses on explainable artificial intelligence (XAI) methods to bridge this gap.[10]

c) Physiologically Based Pharmacokinetic (PBPK) Models

While AI and machine learning models primarily predict *whether* a chemical causes toxicity, physiologically based pharmacokinetic (PBPK) models address a different but equally critical question: *how much of the chemical reaches a target organ, and for how long?* PBPK models divide the body into interconnected compartments-typically including blood, liver, kidney, fat, and other tissues-linked by blood flow equations. Each compartment is characterised by parameters describing absorption, distribution, metabolism, and excretion (ADME). A well-constructed PBPK model can simulate the fate of an orally administered chemical from ingestion through

gastrointestinal absorption, first-pass hepatic metabolism, systemic circulation, tissue distribution, and eventual elimination. These models are exceptionally valuable for extrapolation across different scenarios: from high experimental doses to environmentally relevant low doses, from laboratory animals to humans, and from single chemicals to complex mixtures. Regulatory bodies including the US Environmental Protection Agency and the European Medicines Agency accept validated PBPK models as substitute evidence for certain animal studies, particularly in pesticide safety assessment and pharmaceutical development.[11]



Figure 3: Predictive Models in Toxicology [41]

5. Biomarkers in Toxicology

Biomarkers are now a key part of modern toxicology because they offer measurable signs of how the body reacts to harmful substances.

A biomarker is a biological feature that shows whether someone has been exposed to a chemical or environmental factor, how sensitive they are to it, or what effects it has caused. Previously, toxicology mainly focused on noticeable symptoms and damage to tissues. But with new advances in molecular biology and analytical tools, it's now possible to detect early changes in the body before serious toxicity occurs.

Biomarkers help us understand how toxic substances interact with living systems.

They are useful for identifying people who might be at risk, tracking how diseases progress, and making safety assessments more reliable. In both pharmaceutical and environmental toxicology, biomarkers are used to find out if a substance harms organs such as the liver, kidneys, or nervous system. The use of biomarkers has greatly improved the accuracy and speed of toxicity testing. [12][13][14]



Figure 4: classification of biomarkers [42]

a) Types of Biomarkers

Biomarkers are usually divided into three main groups: biomarkers of exposure, biomarkers of effect, and biomarkers of susceptibility.

Biomarkers of exposure show that a harmful substance or its breakdown products are present in the body. Examples include blood levels of lead and mercury in urine. These help determine how much someone has been exposed to dangerous chemicals. Biomarkers of effect show how the body responds after exposure. They show changes in biochemical or physical processes within the body. Things like enzyme activity, DNA damage, and signs of oxidative stress are examples of this type.

Biomarkers of susceptibility identify people who may be more sensitive to toxic substances due to genetic or biological reasons. Differences in how genes affect metabolic enzymes often lead to varied reactions to toxins. Classifying biomarkers helps researchers understand how exposure happens and how toxicity develops.[15][16]

b) Genomic and Proteomic Biomarkers

Recent progress in genomics and proteomics has changed how toxicology studies are done.

Genomic biomarkers involve changes in gene activity caused by toxic exposure. Tools like DNA microarrays and next-generation sequencing are used to study genetic changes.

Proteomic biomarkers look at changes in protein levels and function.

Since proteins are involved in many bodily processes, their changes can tell us a lot about how toxins affect the body. New proteomic techniques let scientists detect small molecular changes linked to toxic exposure. Together,

genomic and proteomic biomarkers are part of toxicogenomics, which combines molecular information with toxicological results.
These methods give a better understanding of how toxicity works and help create more personalized risk assessments.[17][18][19]

6. Safety Assessment Approaches

Safety assessment is a systematic process used to evaluate the potential adverse effects of chemicals, pharmaceuticals, and environmental agents on living organisms. The primary objective of safety assessment is to ensure that substances do not pose unacceptable risks to human health or the environment.

Traditionally, safety assessments relied heavily on animal studies to evaluate toxicity. Although these methods have generated valuable information, they are often time-consuming, costly, and associated with ethical concerns. Modern toxicology increasingly adopts integrated approaches involving computational tools, molecular techniques, and predictive models to improve the accuracy of hazard identification.

Safety assessment includes hazard identification, dose-response analysis, exposure assessment, and risk characterization. These components collectively help regulatory agencies establish safety guidelines and permissible exposure limits.[20][21]

a) Risk Assessment

Risk assessment is a scientific process used to estimate the likelihood and severity of adverse health effects caused by exposure to hazardous substances. It serves as a foundation for regulatory decision-making and public health protection.



Figure 5: Risk assessment process [43]

The process of risk assessment generally consists of four major steps:

1. Hazard identification
2. Dose-response assessment
3. Exposure assessment
4. Risk characterization

Hazard identification determines whether a substance can produce harmful effects. Dose-response assessment evaluates the relationship between exposure level and toxic response. Exposure assessment estimates the amount and duration of contact with the chemical. Finally, risk characterization integrates all information to estimate overall risk.

Advances in computational toxicology and biomarker research have enhanced risk assessment procedures by enabling more accurate predictions and reducing uncertainties.[22][23][24]

b) Alternative Testing Methods

Growing ethical concerns regarding animal experimentation have encouraged the development of alternative testing approaches. Modern toxicology aims to reduce, refine, and replace animal use while maintaining reliable safety evaluations.

Alternative testing methods include in vitro assays, organ-on-chip systems, computational modeling, and stem-cell-based testing platforms. Cell culture methods allow researchers to study toxicity responses under controlled conditions without extensive animal usage.

In silico methods use computer simulations and predictive algorithms to estimate toxic effects. Organ-on-chip technologies replicate physiological conditions of human organs, providing more realistic toxicity information.These innovative approaches support efficient and ethical safety assessments while improving the relevance of results to human health.[25][26][27]

7. Modern Technologies in Toxicology

Rapid technological progress has significantly transformed toxicological research. Emerging technologies provide greater sensitivity, speed, and accuracy in toxicity evaluation. Modern approaches integrate biological data, computational techniques, and automation systems to improve understanding of toxic mechanisms. Technological innovations have enabled scientists to analyze thousands of chemicals simultaneously and identify complex biological interactions. These developments contribute to predictive toxicology and facilitate more informed safety decisions.[28][29]



Figure 6: Modern Technologies in Toxicology [44]

a) High-Throughput Screening

High-throughput screening (HTS) is an advanced technology used to rapidly evaluate large numbers of chemicals for biological activity and toxicity potential. Automated systems perform numerous experiments simultaneously using small sample volumes.

HTS platforms provide efficient identification of hazardous compounds and support prioritization of substances requiring further investigation. Programs such as ToxCast use HTS techniques to assess chemical safety and understand toxicity pathways.

The use of HTS significantly reduces testing time and supports the development of predictive models for toxicity assessment.[30][31]

b) Omics and Systems Toxicology

Omics technologies, including genomics, transcriptomics, proteomics, and metabolomics, generate comprehensive datasets describing biological responses to toxic substances.

Systems toxicology combines omics data with computational approaches to understand interactions among genes, proteins, and metabolic pathways. Instead of focusing on isolated biological events, systems toxicology studies toxicity as an integrated network process.

These approaches provide mechanistic insights into toxic responses and support the development of personalized and predictive toxicology models.[32][33]

8. Regulatory and Ethical Considerations

Regulatory frameworks play a critical role in ensuring the safe use of chemicals and pharmaceutical products. Organizations such as international regulatory agencies establish guidelines for toxicity testing and risk evaluation.

Ethical considerations have become increasingly important in toxicology due to concerns regarding animal welfare and responsible research practices. Researchers are encouraged to follow principles that promote humane scientific procedures and minimize unnecessary testing.

Balancing scientific advancement with ethical responsibilities remains an important challenge in modern toxicology.[34][35][36]

9. Challenges and Future Perspectives

Despite significant advancements, toxicology continues to face several challenges. Human biological systems are highly complex, making accurate prediction of toxic responses difficult. Differences in genetics, environmental conditions, and lifestyle factors contribute to variability in toxicity outcomes.

Large-scale biological data generated through omics technologies also create challenges in data interpretation and integration. Additionally, regulatory acceptance of newly developed methods remains a critical issue.

Future toxicology is expected to rely increasingly on artificial intelligence, personalized medicine, and integrated computational approaches. Continued technological progress may lead to safer, faster, and more human-relevant toxicity assessment methods.[37][38]

10. Conclusion

Advances in toxicology have transformed traditional methods of toxicity assessment into more predictive, efficient, and mechanistic approaches. The integration of biomarkers, predictive modeling, and modern technologies has improved the understanding of toxic responses and enhanced safety evaluation processes.

Innovations such as genomic biomarkers, computational models, high-throughput screening, and alternative testing methods have contributed significantly to reducing uncertainty in risk assessment. As technology continues to evolve, toxicology is expected to move toward more precise and personalized approaches that support improved public health protection and ethical scientific practices.

References

1. Mayr, A., Klambauer, G., Unterthiner, T.,&Hochreiter, S. (2016). DeepTox: toxicity prediction using deep learning. Frontiers in Environmental Science, 3, 80.

DOI: 10.3389/fenvs.2015.00080

2.Ewart, L., et al. (2018). Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Communications Medicine, 2, 154.

DOI: 10.1038/s43856-022-00209-1

3.Sistare, F. D.,&DeGeorge, J. J. (2012). Preclinical predictors of clinical safety: a vision for the future. Toxicologic Pathology, 40(2), 169–174.

DOI: 10.1177/0192623311427578

4.Albertini, R. J., et al. (2020). Biomarkers for assessing environmental exposures. Annual Review of Pharmacology and Toxicology, 60, 199–222.

DOI: 10.1146/annurev-pharmtox-010919-023625

5.US EPA. (2021). New Approach Methods Work Plan: Reducing Animal Testing for Pesticide Safety. EPA Document # 740C21003. Available from epa.gov

6.Leist, M., et al. (2014). Adverse outcome pathways: opportunities and limitations for regulatory application. ALTEX, 31(4), 441–457.

DOI: 10.14573/altex.1408191

7.Leist, M., Ghallab, A., Graepel, R., et al. (2017). Adverse outcome pathways: opportunities, limitations and open questions. Archives of Toxicology, 91(11), 3477–3505. DOI: 10.1007/s00204-017-2045-3

8.Basketter, D., Clewell, H., Kimber, I., et al. (2021). A roadmap for the next generation of risk assessment. ALTEX – Alternatives to Animal Experimentation, 38(2), 301–316. DOI: 10.14573/altex.2101111

9.Raies, A. B.,&Bajic, V. B. (2016). In silico toxicology: computational methods for the prediction of chemical toxicity. Wiley Interdisciplinary Reviews: Computational Molecular Science, 6(2), 147–172. DOI: 10.1002/wcms.1240

10.Pushkar, A.,&Singh, H. (2024). Machine learning in predictive toxicology: recent advances and future perspectives. Chemical Research in Toxicology, 37(1), 23–45. DOI: 10.1021/acs.chemrestox.3c00231

11.Lin, Z.,&Clewell, R. A. (2018). Physiologically based pharmacokinetic (PBPK) modeling in regulatory toxicology. In Computational Toxicology (pp. 123–145). Humana Press. DOI: 10.1007/978-1-4939-7899-1_5

12.Mayeux, R. "Biomarkers: Potential Uses and Limitations." NeuroRx, 1(2), 182–188, 2004.

13.Schulte, P.A., & Perera, F.P. Molecular Epidemiology: Principles and Practices. Academic Press, 1993.

14.Wetmore, B.A., et al. "Incorporating Population Variability and Susceptibility into Toxicological Assessments." Toxicological Sciences, 2012.

15.Biomarkers Definitions Working Group. "Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework." Clinical Pharmacology&Therapeutics, 69(3), 89–95, 2001.

16.Strimbu, K., & Tavel, J.A. "What are Biomarkers?" Current Opinion in HIV and AIDS, 5(6), 463–466, 2010.

17.Van Delft, J.H., et al. "A Review of Toxicogenomics in Biomarker Discovery." Nature Biotechnology, 22, 134–145, 2004.

18.Wetmore, B.A., et al. "Incorporating Omics into Toxicological Evaluation." Toxicological Sciences, 125(1), 157–174, 2012.

19.Harrill, A.H., & Rusyn, I. "Systems Biology and Toxicology." Toxicologic Pathology, 36, 199–207, 2008.

20.Eaton, D.L., & Gilbert, S.G. Principles of Toxicology in Safety Assessment. McGraw-Hill Education.

21.Klaassen, C.D. Casarett and Doull's Toxicology: The Basic Science of Poisons, 9th Edition, McGraw-Hill, 2019.

22.National Research Council. Science and Decisions: Advancing Risk Assessment. National Academies Press, Washington DC, 2009.

23.United States Environmental Protection Agency (EPA). Human Health Risk Assessment Guidelines.

24.Paustenbach, D.J. The Practice of Exposure Assessment: A State-of-the-Art Review. Journal of Toxicology, 2000.

25.Hartung, T. "Food for Thought on Alternatives to Animal Testing." ALTEX, 27(1), 3–14, 2010.

26.OECD. Guidance Document on Alternative Methods for Toxicity Testing. Organization for Economic Cooperation and Development.

27.Marx, U., et al. "Biology-inspired Microphysiological Systems to Advance Patient Benefit and Animal Welfare." ALTEX, 37, 365–394, 2020.

28.Krewski, D., et al. "Toxicity Testing in the 21st Century: A Vision and a Strategy." Journal of Toxicology and Environmental Health, 2010.

29.Hartung, T. "Toxicology for the Twenty-First Century." Nature, 460, 208–212, 2009.

30.Kavlock, R.J., et al. "Update on EPA's ToxCast Program." Environmental Health Perspectives, 120(12), 1678–1684, 2012.

31.Judson, R.S., et al. "Perspectives on Validation of High-Throughput Assays." Toxicological Sciences, 2013.

32.Waters, M.D., & Fostel, J.M. "Toxicogenomics and Systems Toxicology." Annual Review of Pharmacology and Toxicology, 44, 315–338, 2004.

33.Sauer, U.G., et al. "Systems Toxicology Approaches." Archives of Toxicology, 91, 417–432, 2017.

34.OECD. Guidance Document on Regulatory Toxicology and Safety Evaluation.

35.World Health Organization (WHO). Environmental Health Criteria Reports.

36.National Research Council. Toxicity Testing in the 21st Century: A Vision and Strategy., 2007.

37.Krewski, D., et al. "Evolution of Toxicity Testing Paradigms." Toxicological Sciences, 2020.

38.Hartung, T., & Leist, M. "Food for Thought: The Future of Toxicology." ALTEX, 2008.

39.Krewski D, et al. Toxicity Testing in the 21st Century: A Vision and a Strategy. Journal of Toxicology and Environmental Health, 2010.

40.Raies AB, Bajic VB. In Silico Toxicology: Computational Methods for the Prediction of Chemical Toxicity. 2016.

41.Pushkar A, Singh H. Machine Learning in Predictive Toxicology. 2024.

42.Strimbu K, Tavel JA. What are Biomarkers? 2010.

43.National Research Council. Science and Decisions: Advancing Risk Assessment. 2009.

44. Sauer U.G., et al. Systems Toxicology Approaches. Archives of Toxicology, 2017.ictive Models in Toxicology